Abstract: The present disclosure relates to methods, products and systems for the prognosis of subjects suffering from multiple myeloma. In certain embodiments, the present disclosure provides a method of prognosis for a subject suffering from multiple myeloma. The method comprises determining the level of desmoglein 2 (DSG2) in malignant plasma cells from the subject, wherein an increased level of DSG2 in the plasma cells is indicative of a poorer prognosis for the subject.
Type:
Application
Filed:
November 16, 2021
Publication date:
April 4, 2024
Applicants:
University of South Australia, Central Adelaide Local Health Inc, The University of Adelaide
Inventors:
Craig Thomas Wallington-Beddoe, Claudine Sharon Bonder, Lisa Michelle Ebert